Grapiprant
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Grapiprant, covering 2025-06-13 to 2025-06-13. Get the full timeline:
Most recent: Clinical Trial Update: Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer [Phase 1, Phase 2]